Abstract
This cohort study evaluates early treatment trends of oral semaglutide among adults eligible for obesity management medications following its approval for obesity.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureYuqing Lei, Xinyao Jian, David A. Asch
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Once-weekly semaglutide in adults with overweight or obesity.
10.1056/nejmoa2032183 · 2021
Oral semaglutide at a dose of 25 mg in adults with overweight or obesity.
10.1056/nejmoa2500969 · 2025
Food and Drug Administration’s obesity drug guidance document: a short history.
10.1161/circulationaha.111.028381 · 2012
Uptake of and disparities in semaglutide and tirzepatide prescribing for obesity in the US.
10.1001/jama.2025.4735 · 2025
Orforglipron: first approval.
10.1007/s40265-026-02363-5 · 2026
What to know about the new semaglutide pill for obesity.
10.1001/jama.2026.0035 · 2026
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
No additional external references are available.